Physician profile
Eun Ko
NPI 1932542891
$16,368.98
in general payments reported to CMS, 2019-2025
50 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,881 · 2020: $1,976 · 2021: $2,910 · 2022: $2,808 · 2023: $2,672 · 2024: $2,432 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,770 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,769.59 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,888.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,725.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,535.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,479.75 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $1,371.80 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $918.40 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $915.27 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $806.76 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $799.25 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $586.34 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $560.95 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $531.77 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $422.55 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $344.74 | 2022-2025 | |
| Astellas Pharma US INC | $298.15 | 2019-2025 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eun Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.